Skip to search boxSkip to navigationSkip to main content

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population

  • Chris Kay
    ,
  • Jennifer A. Collins
    ,
  • Galen E.B. Wright
    ,
  • Fiona Baine
    ,
  • Zosia Miedzybrodzka
    ,
  • Folefac Aminkeng
  • University of British Columbia
    ,
  • University of Cape Town
    ,
  • School of Pathology
    ,
  • University of Aberdeen
    ,
  • Agency for Science, Technology and Research, Singapore
    ,
  • Coriell Institute for Medical Research
Research Output:
Contribution to journal
Article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 346-357 (12 pages)

Journal (Volume, Issue Number)

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics (Volume 177, Issue 3)

Publication milestones

  • Published - 04/2018

Publication status

Published - 04/2018

ISSN

1552-4841

Publication IDs

  • Scopus: 85042129154
  • PubMed: 29460498

Abstract

Huntington disease (HD) is the most common monogenic neurodegenerative disorder in populations of European ancestry, but occurs at lower prevalence in populations of East Asian or black African descent. New mutations for HD result from CAG repeat expansions of intermediate alleles (IAs), usually of paternal origin. The differing prevalence of HD may be related to the rate of new mutations in a population, but no comparative estimates of IA frequency or the HD new mutation rate are available. In this study, we characterize IA frequency and the CAG repeat distribution in fifteen populations of diverse ethnic origin. We estimate the HD new mutation rate in a series of populations using molecular IA expansion rates. The frequency of IAs was highest in Hispanic Americans and Northern Europeans, and lowest in black Africans and East Asians. The prevalence of HD correlated with the frequency of IAs by population and with the proportion of IAs found on the HD-associated A1 haplotype. The HD new mutation rate was estimated to be highest in populations with the highest frequency of IAs. In European ancestry populations, one in 5,372 individuals from the general population and 7.1% of individuals with an expanded CAG repeat in the HD range are estimated to have a molecular new mutation. Our data suggest that the new mutation rate for HD varies substantially between populations, and that IA frequency and haplotype are closely linked to observed epidemiological differences in the prevalence of HD across major ancestry groups in different countries.

Funding Details

Funding for this study was provided by the Canadian Institutes of Health Research (CIHR: MOP-84438). Dr. Kay was funded by a Canadian Institutes of Health Research Doctoral Research Award. Dr. Hayden is an employee with financial interests in Teva Pharmaceuticals Ltd. and funded by an operating grant from the Canadian Institutes of Health Research. We wish to acknowledge the many patients and families from clinics worldwide who contributed to this study. Canadian Institutes of Health Research, Grant number: MOP-84438; Canadian Institutes of Health Research Doctoral Research Award
FundersFunding numbers
Canadian Institutes of Health Research Doctoral Research Award
-
Teva Pharmaceuticals Ltd.
-
CIHR
MOP-84438

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
99
Citations
61
Mentions
1

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well